Investigational Device Exemption (IDE) for the development of OBI-888 was approved by the US Food and Drug Administration (FDA) for its use in OBI-888 Phase I cohort expansion phase

Date of occurrence of the event: Nov 12, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: OBI received a letter from the US Food and Drug Administration (FDA) on Nov 10 (US time) that the Investigational Device Exemption […]